Detalles de la búsqueda
1.
Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice.
Diabetes Obes Metab
; 24(3): 391-401, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34704329
2.
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Diabetes Obes Metab
; 22(3): 458-462, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31486230
3.
Favorable Effect of Pemafibrate on Insulin Resistance and ß-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.
Pharmaceutics
; 15(7)2023 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37514025
4.
Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function.
Sci Rep
; 12(1): 9740, 2022 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35697838
5.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
J Diabetes Investig
; 12(8): 1395-1399, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33325645
6.
Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing ß-Cell Mass in db/db Mice.
Diabetes
; 70(4): 917-931, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33608422
7.
Glucokinase is required for high-starch diet-induced ß-cell mass expansion in mice.
J Diabetes Investig
; 12(9): 1545-1554, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33638884
8.
Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
Diabetes Res Clin Pract
; 180: 109069, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34563585
9.
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
J Diabetes Investig
; 12(8): 1417-1424, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33421309
10.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
BMJ Open
; 10(2): e034883, 2020 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32034028
Resultados
1 -
10
de 10
1
Próxima >
>>